Indication for the treatment of acid-reflux disorders (gerd), peptic ulcer disease, active benign gastric ulcer, and active duodenal ulcer.pharmacodynamics nizatidine is a competitive, reversible inhibitor of histamine at the histamine h2-receptors, particularly those in the gastric parietal cells. by inhibiting the action of histamine on stomach cells, nizatidine reduces stomach acid production. nizatidine had no demonstrable antiandrogenic action. full-dose therapy for the problems treated by nizatidine lasts no longer than 8 weeks. it has been demonstrated that treatment with a reduced dose of nizatidine is effective as maintenance therapy following healing of active duodenal ulcers.mechanism of action nizatidine competes with histamine for binding at the h2-receptors on the gastric basolateral membrane of parietal cells. competitive inhibition results in reduction of basal and nocturnal gastric acid secretions.
Voir plus de détails